B. Riley initiated coverage of Vanda Pharmaceuticals (VNDA) with a Buy rating and $11 price target The firm says Vanda is a commercial-stage turnaround story trading at a “historic discount.” The company is heading into two potential approvals within three months and “clearing of multiple overhangs that have kept investors on the sidelines,” the analyst tells investors in a research note. It believes the stock’s current negative enterprise value represents an attractive entry point.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress
- Vanda Pharmaceuticals reports Q3 EPS (38c), consensus (45c)
- Vanda Pharmaceuticals sees FY25 revenue $210M-$250M, consensus $224.84M
- Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study